Plumbagin analogs—synthesis, characterization, and antitubercular activity

Nishi Nayak, Meenakshi Bajpai¹, Balkishen Razdan²
Pursuing Ph.D., and ¹Professor, Faculty of Pharmacy, Uttarakhand Technical University, Dehradun, ²Ex-Professor, Department of Pharmaceutical Sciences, BIT, Mesra, Ranchi, Jharkhand, India

Abstract
Considering the emerging problem of drug resistance in tuberculosis, there is an urgent need of development of new analogs that are useful in curing drug resistant tuberculosis. In India, tuberculosis continues to remain one of the most pressing health problems. India is the highest tuberculosis burden country in the world, accounting one fifth of global incidence - estimated 2.0-2.5 million cases annually. In 2011, approximately 8.7 million new cases of tuberculosis and 1.4 million people die from tuberculosis each year worldwide. Current antitubercular therapies are successful against normal tuberculosis but it is not suitable for drug resistant tuberculosis. In this study Plumbagin analogs, obtained from Plumbago zeylanica (Family-Plumbaginaceae), have been synthesized. Out of the various synthesized analogs, the antitubercular activity of compound a and b was evaluated using standard H₃⁷Rv and S, H, R, and E sensitive M tuberculosis strains using LRF assay method. Compound a showed strong activity against both standard H₃⁷Rv and S, H, R and E sensitive M. tuberculosis strains as compared to standard Rifampicin. The other compounds are proved to be more active against standard H₃⁷Rv and S, H, R and E sensitive M. tuberculosis strain as compared to Rifampicin.

Key words: Ethambutol (R), isoniazid (h), plumbagin, rifampicin (r)

INTRODUCTION
Tuberculosis is an airborne disease caused by the bacterium Mycobacterium tuberculosis. M. tuberculosis and seven other related mycobacterial species (M. bovis, M. africanum, M. microti, M. caprae, M. pinnipedii, M. canetti and M. mungi) together form M. tuberculosis complex. Most but not all species have been found to cause disease in humans.[1] Multidrug-resistant TB (MDR TB) is caused by organisms resistant to the most effective anti-TB drugs, isoniazid and rifampin. These drugs are considered first-line drugs and are used to treat most persons with TB disease. Extensively drug-resistant TB (XDR TB) is a relatively rare type of drug-resistant TB. XDR TB is resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs (i.e. amikacin, kanamycin, or capreomycin).[2]

The multidrug resistance, reinfection, and latent infection has become the major cause of concern for the treatment of tuberculosis in all over the world. This together with the problem of the interactions of the current tuberculosis drugs with the antiretroviral drugs taken by HIV positive people, means that there is an urgent need for new tuberculosis drugs.[3]

Plants containing 1,4-naphthoquinone derivatives were shown promising antitubercular activity with novel mode of action and their synthetic derivatives. Plumbagin have naphthoquinone moiety which inhibits menaquinone pathway which is essential for the growth of M. tuberculosis and M. smegmatis.[4]

Esters of 5-hydroxyl group of Plumbagin have been reported to have activity against Mycobacterium species,[5]
MATERIALS AND METHODS

Materials
Plumbagin was purchased from Sigma-Aldrich, Germany. 1-Naphtholyl chloride, 2-Naphtholyl chloride, Hexanoyl chloride, and Pyrazinamide were purchased from Sigma-Aldrich, Germany. Isoniazid and Ethionamide provided by Themis medicare as a gift samples. The IR spectra were recorded on a IR spectrometer Carry 630. The 1H NMR spectra have been recorded on Bruker 400 Avance Fourier Transform Spectrometer operating at 400 mega hertz in deuterated dimethylsulfoxide (DMSO) with all shifts referred to internal tetramethylsilane (TMS). The mass spectra were recorded on a LCMS Agilent Technology model 6520. All other reagents used in synthesis as well as analysis were of synthetic grade and analytical grade, respectively.

Methods
Plumbagin derivatives have been synthesized as per the following scheme given in the following

a. Treatment with Acyl chloride

\[ \text{Plumbagin} + \text{RCOCI} \rightarrow \text{Product} \]

b. Chlorination of methyl group of plumbagin

\[ \text{Plumbagin} + \text{Sulphuryl chloride} \rightarrow \text{Chlorinated Product} \]

c. Condensation with antitubercular drugs

\[ \text{Plumbagin} + \text{Antitubercular Drug} \rightarrow \text{Condensation Product} \]

Where  \( R = 1\)-Naphthoyl chloride, 2-Naphthoyl chloride, Hexanoyl chloride  
\( R_1 = \) Ethionamide, Pyrazinamide, Isoniazid

The steps involved in synthesis of plumbagin derivatives included

Step 1: Plumbagin was dissolved in dichloromethane and pyridine at 0°C and reaction was maintained in an ice-bath. Solution was stirred for 5 min. Acid chlorides were added dropwise to the reaction mixture at 0°C. Reaction mixture further stirred for 3 h at room temperature. After 3 h, reaction mixture was diluted with dichloromethane and washed with water and brine solution. Products were separated using separating funnel. Oily product obtained. Reaction was confirmed by an IR spectrum.

Step 2: To the step 1 product, ethanol was added. Further, sulphuryl chloride and benzoyl peroxide were added to the reaction mixture. Stirred it for 2 h at room temperature and dried it in oven at 50°C. Reaction was confirmed by an IR spectrum.

Step 3: To the step 2 product, ethanol and anti-tubercular drug were added. Refluxed for 3 h and dried it in an oven at 50°C. Final product was confirmed by an IR spectrum and TLC both.

Compound a: 2-[(2’-Ethylisonicotinoylthiamido)-methyl-5-(1’-naphthoyl)-oxy]-1,4-naphthoquinone

Compound b: 2-(Pyrazinecarboxamido)-methyl-5-(1’-naphthoyl)-oxy-1,4-naphthoquinone

Compound c: 2-[(2’-Isonicotinoylhydrazino)-methyl-5-(1’-naphthoyl)-oxy]-1,4-naphthoquinone
Compound d: 2-(2'-Ethylisonicotinoylthiamido)-methyl-5-(2'-naphthoyl)-oxy-1,4-naphthoquinone

Compound e: 2-(Pyrazinecarboxamido)-methyl-5-(2'-naphthoyl)-oxy-1,4-naphthoquinone

Compound f: 2-(2'-Isonicotinoylhydrazino)-methyl-5-(2'-naphthoyl)-oxy-1,4-naphthoquinone

Compound g: 2-(2'-Ethylisonicotinoylthiamido)-methyl-5-(n-hexanoyl)-oxy-1,4-naphthoquinone

Compound h: 2-(Pyrazinecarboxamido)-methyl-5-(n-hexanoyl)-oxy-1,4-naphthoquinone

Compound i: 2-(2'-Isonicotinoylhydrazino)-methyl-5-(n-hexanoyl)-oxy-1,4-naphthoquinone

**Compound a**
This was synthesized using above scheme. Rf 0.44 (Silica Gel G, n-hexane: EtOAc, 10:2); IR (cm⁻¹) 3067 (Aromatic C-H), 2985 (Aliphatic-CH₂), 1678 (Aryl C = C), 1631 (C = O), 1452 (Aromatic ring stretch); (400 MHz, DMSO-d₆), δH ppm: 2.469 (1H, s), 3.025–3.006 (4H, q, J = 7.6 Hz), 1.258–1.240 (3H, t, J = 7 Hz), 6.998 (1H, m), 7.126 (1H, m), 7.254 (1H, m), 7.468 (1H, m), 7.536 (1H, m), 7.552 (1H, m), 7.574 (1H, m), 8.076 (1H, m), 7.969 (1H, s), 7.900 (1H, s), 8.605 (1H, s); m/z 507.13(M⁺).

**Compound b**
This was synthesized using above scheme. Rf 0.46 (Silica Gel G, hexane: EtOAc, 10:2); IR (cm⁻¹) 3423 (Aromatic C-H), 2965 (Aliphatic-CH₃), 1678 (Aryl C = C), 1596 (C = O), 1169 (Amide C = O); (400 MHz, DMSO-d₆), δH ppm: 2.469 (1H, s), 7.993–7.973 (2H, d, J = 8 Hz), 7.629 (1H, m), 7.326 (1H, m), 7.609 (1H, m), 7.591 (1H, m), 7.574 (1H, m), 7.555 (1H, m), 8.241 (1H, m), 7.845 (1H, s); m/z 464.12(M⁺).

**Compound c**
This was synthesized using above scheme. Rf 0.43 (Silica Gel G, hexane: EtOAc, 10:2); IR (cm⁻¹) 3216 (Aromatic C-H),
2121 (Aliphatic-CH₂), 1659 (Aryl C = C), 1544 (C = O), 1413 (Aromatic ring stretch), 1287 (Amide C = O); (400 MHz, DMSO-d₆), dH ppm: 2.469 (1H, s), 7.700-7.687 (2H, d, J = 7.8 Hz), 7.763-7.748 (2H, d, J = 6 Hz), 7.443 (1H, m), 7.462 (1H, m), 7.481 (1H, m), 7.531 (1H, m), 7.551 (1H, m), 7.566 (1H, m), 7.583 (1H, m); m/z not clear.

**Compound d**

This was synthesized using above scheme. R, 0.41 (Silica Gel G, n-hexane: EtOAc, 10:2); IR (cm⁻¹) 3052 (Aromatic C-H), 2821 (Aliphatic-CH₃), 1683 (Aryl C = C), 1428 (Aromatic ring stretch), 1240 (C = S); (400 MHz, DMSO-d₆), dH ppm: 3.691-3.673 (4H, q, J = 6.8), 1.067-1.049 (3H, t, J = 6.4 Hz), 2.469 (1H, s), 7.923 (1H, s), 7.903 (1H, s), 6.839 (1H, s); m/z 501.13[M⁺].

**Compound e**

This was synthesized using above scheme. R, 0.38 (Silica Gel G, hexane: EtOAc, 10:2); IR (cm⁻¹) 3421 (Aromatic C-H), 3090 (Aliphatic-CH₂), 1702 (Aryl C = C), 1672 (Aromatic C = O), 1432 (Aromatic ring stretch), 1173 (Amide C = O); (400 MHz, DMSO-d₆), dH ppm: 8.235 (1H, s), 2.468 (1H, s), 7.91 (1H, m), 7.89 (1H, m), 7.83 (1H, m), 7.204 (1H, m), 7.077 (1H, m), 6.949 (1H, m), 8.238 (1H, m); m/z 464.12(M⁺).

**Compound f**

This was synthesized using above scheme. R, 0.44 (Silica Gel G, hexane: EtOAc, 10:2); IR (cm⁻¹) 3197 (Aromatic C-H), 2519 (Aliphatic-CH₂), 1682 (Aryl C = C), 1659 (Aromatic C = O), 1413 (Aromatic ring stretch), 1283 (Amide C = O); (400 MHz, DMSO-d₆), dH ppm: 9.153 (1H, s), 8.824-8.818 (2H, m, J = 0.36 Hz), 8.63 (1H, s), 6.957 (1H, s), 2.469-2.324 (2H, q, J = 8.7 Hz); m/z not clear.

**Compound g**

This was synthesized using above scheme. R, 0.50 (Silica Gel G, n-hexane: EtOAc, 10:2); IR (cm⁻¹) 3391 (Aromatic C-H), 2117 (Aliphatic-CH₂), 1640 (Aryl C = C), 1443 (Aromatic ring stretch), 1190 (C = S); (400 MHz, DMSO-d₆), dH ppm: 2.469 (1H, s), 1.069-1.052 (3H, t, J = 6.7 Hz), 1.197-1.181 (3H, t, J = 6.4 Hz), 3.724-3.707 (5H, p, J = 6.8 Hz), 6.979 (1H, s), 7.107 (1H, s), 7.235 (1H, s); m/z 451.16(M⁺).

**Compound h**

This was synthesized using above scheme. R, 0.47 (Silica Gel G, hexane: EtOAc, 10:2); IR (cm⁻¹) 3427 (Aromatic C-H), 2933 (Aliphatic-CH₂), 1665 (Aryl C = C), 1598 (Aromatic C = O), 1460 (Aromatic ring stretch), 1169 (Amide C = O); (400 MHz, DMSO-d₆), dH ppm: 2.469 (1H, s), 1.210-1.201 (3H, t, J = 3.6 Hz), 1.191-1.178 (3H, t, J = 5.2 Hz), 2.145 (1H, s), 7.847 (1H, s), 7.949-7.933 (2H, d, J = 6.4 Hz); m/z 408.15(M⁺).

**Compound i**

This was synthesized using above scheme. R, 0.52 (Silica Gel G, hexane: EtOAc, 10:2); IR (cm⁻¹) 3197 (Aromatic C-H), 1626 (Aryl C = C), 1551 (Aromatic C = O), 1413 (Aromatic ring stretch), 1063 (Amide C = O); (400 MHz, DMSO-d₆), dH ppm: 2.469 (1H, s), 1.077-1.050 (3H, t, J = 10.8 Hz), 1.190-1.180 (3H, t, J = 4 Hz), 7.697-7.683 (2H, d, J = 5.6 Hz), 7.783-7.768 (2H, d, J = 6 Hz); m/z not clear.

**Mycobacterial growth inhibitory assay**

**Luciferase Reporter Phage (LRF) Assay**

Standard strain H₃₇Rv, a clinical sensitive M. tuberculosis strain and a clinical isolate S, H, R, and E sensitive M. tuberculosis strain were grown in Middlebrook 7H complete medium with and without extracts of samples for 3 days at 37°C. Luciferase Reporter Phage Assay was done using concentrations of 50 and 100 μg/ml of samples. Rifampicin was included as an assay control and DMSO as the solvent control. LRP phage AETRC21 was added and the samples were incubated for four hours. Equal volume of the cell phase mixture was mixed with 0.3 Mm D-Luciferin in 0.05 M sodium citrate buffer of pH 4.5 and light output was immediately measured as RLU (Relative light units) in the luminometer at 10 s integration. Compounds exhibiting a reduction of 50% or more in RLU in the test vials compared to that of the control were considered to have antimycobacterial activity. These LRP assays offer an elegant means of detecting viable mycobacteria and provide a rapid tool for drug susceptibility screening.

**RESULTS AND DISCUSSION**

Plumbagin analogs and its ester were synthesized. Plumbagin has been referred to possess antitubercular activity. Accordingly, various newer analogs have been synthesized and tested for their antitubercular activity. Compounds were synthesized by treating Plumbagin with 1-Naphthoyl chloride, 2-Naphthoyl chloride and Hexanoyl chloride. Further the synthesized Plumbagin derivatives were condensed with antitubercular drugs- Isoniazid, Pyrazinamide, and Ethionamide. IR spectra of synthesized compounds exhibit a band in the region IR spectra confirmed the formation of product. Further, formations of compounds were confirmed by Proton NMR and Mass Spectra. Calculating log P values revealed that among synthesized compounds Ethionamide analogs of Plumbagin possess best Antitubercular activity. Thus, 1-Naphthoyl chloride and Hexanoyl chloride analogs of plumbagin synthesized by condensation of Ethionamide were sent to National Institute for Research in Tuberculosis (ICMR), Chennai for screening of Antitubercular activity. The compounds were screened in both standard H₃₇Rv and clinical isolate S, H, R, and E sensitive M. tuberculosis strain with taken Rifampicin as a standard drug. Compounds b showed better Antitubercular activity as compared to Rifampicin against standard H₃₇Rv M. tuberculosis strain while Compounds showed alone best Antitubercular activity as compared to Rifampicin against clinical isolate S, H, R, and E sensitive M. tuberculosis strain. Out of various compounds, compounds a (1-Naphthoyl...
chloride-Ethionamide derivative of Plumbagin) was found to be most effective in clinical isolate: S, H, R and E sensitive M. tuberculosis [Tables 1 and 2].

**CONCLUSION**

Based on the computational studies, all the synthesized compounds must possess Antitubercular activity. The Antitubercular activity showed that compounds can cure tuberculosis against standard H₃₇Rv strain but compounds (approx. 98% reduction) have more potential to cure tuberculosis against clinical isolate S, H, R and E sensitive M. tuberculosis strain as compared to Rifampicin (approx 16% reduction). Thus, compounds will be beneficial for multidrug resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB).

**ACKNOWLEDGMENTS**

The authors thank Mr. K.K. Jain, who helped us in procurement of drug samples. The authors acknowledge with thanks Dr. Saumya Swaminathan and Dr. Prabhu Seeniyasan (National Institute for Research in Tuberculosis, Chennai) for carrying out Antimycobacterial Activity.

**REFERENCES**

1. Available from: http://www.cdc.gov/features/tbsymptoms/[10/09/2013].
2. Mak A, Thomas A, Del Granado M, Zaleskis R, Mouzafarova N, Menzies D. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 2008;178:306-12.
3. Available from: http://www.who.int/tb/challenges/mdr[10/09/2013].
4. Newton LAA, Cowham E, Sharp D, Leslie R and Davis J. Plumbagin: A natural product for smart materials? N J Chem 2010;34:395-7.
5. Matthew R, Kruthiventi AK, Prasad JV, Kumar SP, Srinu G, Chatterji D. Inhibition of mycobacterial growth by plumbagin derivatives. Chem Biol Drug Des 2010;76:34-42.
6. Datta BS, Hassan G, Kadri SM, Qureshi W, Kamili MA, Singh H, et al. Multidrug-Resistant and extensively drug resistant tuberculosis in Kashmir, India. J Infect Dev Ctries 2010;4:19-23.
7. Jachak SM, Saklani A. Challenges and opportunities in drug discovery from plants. Curr Sci 2007;92:1251-7.
8. Kuete V, Tangmouo JG, Meyer JJ, Lall N. Diospyrone, crassiflorone and plumbagin: Three antimycobacterial andantigonorrhoeal naphthoquinones from two Diospyros spp. Int J Antimicrob Agents 2009;34:322-5.
9. de Paiva SR, Figueiredo MR, Aragão TV, Kaplan MA. Antimicrobial activity *in vitro* of plumbagin isolated from Plumbago species. Mem Inst Oswaldo Cruz 2003;98:959-61.
10. Mital A, Mahlavat S, Bindal S, Sonawane M and Negi V. Synthesis and biological evaluation of alkyl/arylamino derivatives of naphthalene-1,4-dione as antimycobacterial agents. Ther Pharm Chem 2010;2:309-15.
11. Padhye S, Dandawate P, Yusufi M, Ahmad A, Sarkar FH. Perspectives on medicinal properties of plumbagin and its analogs. Med Res Rev 2012; 32:1131-58.
12. Borhade P, Deshmukh T, Patil V and Khandewal K. Review on plumbagin obtained from plumbago zeylanica linn. Int J Pharm Sci Res 2013; 18:116-20.
13. Van der kooy F. University of Pretoria etd, Structure Activity relationship of Naphthoquinone. 2007. p. 1-28.

**Table 1: Percentage reductions in relative light units (RLU) by 50 μg/ml against H₃₇Rv Standard and Clinical isolate: S, H, R, and E sensitive Mycobacterium tuberculosis**

| Compound code | H₃₇Rv Standard | Clinical isolate: S, H, R and E sensitive |
|---------------|----------------|-----------------------------------------|
| A             | 97.99          | 99.03                                   |
| B             | 0              | 7.78                                    |
| Rifampicin (2 μg/ml) | 97.54        | 16.93                                   |

RLU: Relative light units

**Table 2: Percentage reductions in relative light units (RLU) by 100 μg/ml against H₃₇Rv Standard and Clinical isolate: S, H, R, and E sensitive Mycobacterium tuberculosis**

| Compound code | H₃₇Rv Standard | Clinical isolate: S, H, R, and E sensitive |
|---------------|----------------|-----------------------------------------|
| A             | 98.23          | 99.05                                   |
| B             | 49.87          | 8.67                                    |
| Rifampicin (2 μg/ml) | 97.54        | 16.93                                   |

RLU: Relative light units